",n.parentNode.insertBefore(a,n)};if(!!document.cookie.match(/cookieConsent=true/))window.gaf(); ',{'forceSSL':true});


scientific advisory board

marc b. garnick, md 

   Marc B. Garnick, MD is an internationally renowned expert in medical oncology and urologic cancer at Beth Israel Deaconess Medical Center (BIDMC) and the Gorman Brothers Professor of Medicine at Harvard Medical School. He has dedicated his career to the development of new therapies for the treatment of prostate cancer.  Dr. Garnick is a Gorman Brothers Clinical Professor of Medicine, Medicine at Harvard Medical School, and a Gorman Brothers Professor of Medicine at Beth Israel Deaconess Medical Center. 

   Dr. Garnick has extensive knowledge and expertise in oncology cultivated through more than 30 years of teaching at Harvard Medical School, clinical research investigations and leadership of numerous research projects, national committees and advisory boards.  Dr. Garnick has authored more than 300 scientific publications and book chapter, primarily in the area of clinical oncology.

    James is a medical oncologist with 20 years’ experience as a biotechnology executive.  He most recently served as President and Chief Medical Officer at Adventrx Pharmaceuticals. From 2003 to 2006, James was founding CEO of Imagine Pharmaceuticals, a venture company with a small molecule approach to facilitate drug uptake across the blood-brain barrier. He began his industrial career at the Upjohn Company leading early-stage oncology and infectious diseases clinical research. He played a crucial role in launching Upjohn’s HIV research program. James subsequently held senior management positions at IDEC Pharmaceuticals, now Biogen Idec, Viagene Inc., and Introgen Therapeutics.  He successfully advanced groundbreaking biological modalities, such as therapeutic monoclonal antibodies for cancer and rheumatologic diseases and retroviral and adenoviral gene transfer technologies for cancer and HIV. 

    James graduated from Johns Hopkins University and received an M.D. from the University of Vermont. He trained in Internal Medicine and Medical Oncology at the University of Wisconsin from 1977 to 1985 and was appointed Assistant Scientist in the Biophysics Laboratory.

james merritt, md

patrice p. rioux, md, phd


      President of pRx Consulting providing drug development consulting for several biopharmaceutical companies, Dr. Rioux has served as Chief Executive Officer at Thiogenesis and Chief Medical Officer at AltiBio and Edison in addition to senior positions at Repligen and Biogen.  Dr. Rioux handled Clinical and Medical affairs, Clinical Pharmacology and Operations and Pharmacovigilance at Raptor Pharmaceuticals where he simultaneously submitted and received European and USA drug approvals.  His expertise includes early development in metabolic diseases, CNS, immunology, oncology and regulatory affairs related to Orphan Drug Designation and IND filing.

   Dr. Rioux received his Medical Education at Faculté de Médecine-Salpêtrière, his Ph.D. in Mathematical statistics at Faculté des Sciences, and his Degree of Pharmacology at Faculté de Médcine-Salpêtrière.

board of directors

george colberg

ceo, executive chairman

neal nordstom

president and ceo of veridiam

john evey

managing director, bio impact fund

© 2020 Kalos Therapeutics. All Rights Reserved.

This website makes use of cookies. Please see our privacy policy for details.